New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
05:19 EDTGWPHGW Pharmaceuticals receives Fast Track designation for Epidiolex
GW Pharmaceuticals announced that the FDA has granted Fast Track designation to GW's investigational cannabidiol product, Epidiolex, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome. Following receipt earlier in 2014 of orphan drug designation by the FDA in LGS, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and expects to conduct two Phase 3 trials in LGS during 2015.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 14, 2014
07:50 EDTGWPHGW Pharmaceuticals shares attractive ahead of data, says Leerink
After meeting with management, Leerink says is continue to view shares of GW Pharmaceuticals as attractive here ahead of additional Epidiolex data readouts and the commencement of pivotal trials in the second half of 2014. The firm reiterates an Outperform rating on the stock with a $110 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use